Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
respiratory syncytial virus vaccine (recombinant, adjuvanted)
- Development stage
- Approved
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
RSVpreF3-AS01 (marketed as Arexvy) is a recombinant, adjuvanted protein subunit vaccine developed by GSK for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV). The vaccine consists of a recombinant RSV glycoprotein F stabilized in its pre-fusion conformation (RSVPreF3) combined with GSK's proprietary AS01E adjuvant system. The adjuvant system contains the TLR4 agonist 3-O-desacyl-4'-monophosphoryl lipid A (MPL) and the saponin QS-21 in a liposomal formulation to enhance the immune response. Arexvy is approved for active immunization in adults aged 60 years and older, as well as adults aged 18 to 59 years who are at an increased risk of severe RSV disease. It is also being evaluated in clinical trials for other high-risk populations, such as immunocompromised transplant recipients, and to assess its potential cardiovascular benefits.
- Brand names
- Arexvy
- Other names
- recombinant respiratory syncytial virus pre-fusion F protein (RSVPreF3) (AS01E adjuvanted vaccine)respiratory syncytial virus vaccine (recombinant, adjuvanted)RSVPreF3 OARSVPreF-3 OARSVPreF 3 OARSVPreF3 OA vaccineRSVPreF-3 OA vaccineRSVPreF 3 OA vaccineRSVPreF3-AS01RSVPreF-3-AS01RSVPreF 3-AS01RSVPreF3-AS01ERSVPreF-3-AS01ERSVPreF 3-AS01E
02
Targets
RSV F (Respiratory syncytial virus fusion protein)
Beyond the preview
Go deeper on respiratory syncytial virus vaccine (recombinant, adjuvanted).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on respiratory syncytial virus vaccine (recombinant, adjuvanted).